Is Royalty Pharma plc (RPRX) a Buy, Sell, or Hold?
NASDAQ : RPRX
Royalty Pharma plc — Analyst Ratings
$58.83 USD
-$0.19 (-0.32%)
- Volume
- 2.11M
- Average Volume
- 3.75M
- Market Capitalization
- $25.3B
- P/E Ratio
- 23.87
- Dividend Yield
- 1.55%
- Price Target
- $57.00
- Year High
- $59.72
- Year Low
- $34.08
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.47
- Current Ratio
- $2.66
Analyst Consensus Summary
Consensus Rating
Neutral
11 Analysts
Rating Score
3/5
Recommendation Strength
Upside/Downside
3.2%
vs Current Price
Price Target
$57.00
Average TargetPrice Target Range
Lowest Target
$50.00
17.7% UPSIDE
Average Target
$57.00
Median Estimate
Highest Target
$63.00
-6.6% DOWNSIDEAnalyst Breakdown
Overall Consensus: Buy | Total Analysts: 11
| Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|
| 0 | 11 | 0 | 0 | 0 |
Analyst Ratings (Detailed)
| Analyst Company | Analyst Name | Price Target | Price When Posted | Date | Upside/Downside |
|---|---|---|---|---|---|
| UBS | Ashwani Verma | $57 | $49.3 | 2026-04-21 07:14 AM | 15.6% |
| Morgan Stanley | Terence Flynn | $63 | $47.9771 | 2026-04-10 08:56 AM | 31.3% |
| Morgan Stanley | Terence Flynn | $61 | $44.7115 | 2026-02-12 08:14 AM | 36.4% |
| UBS | Ashwani Verma | $49 | $40.86 | 2026-01-30 04:40 AM | 19.9% |
| Morgan Stanley | Terence Flynn | $54 | $36.1419 | 2025-07-10 08:34 AM | 49.4% |
| Goldman Sachs | Chris Shibutani | $51 | $29.155 | 2024-09-04 03:44 AM | 74.9% |
| Morgan Stanley | Terence Flynn | $51 | $25.73 | 2024-07-11 04:15 AM | 98.2% |